4basebio wins deal to supply clinical-grade DNA for pharma client’s Phase I cell therapy trial
Bitget2026/09/28 06:03- 4basebio will supply clinical-grade opDNA DNA starting material for a multinational pharmaceutical company’s Phase I cell therapy trial.
- TriLink BioTechnologies was selected as CDMO to manufacture the mRNA drug substance using its CleanCap co-transcriptional capping technology.
- Deal extends an existing Tier 1 pharma customer relationship into cell therapy programs, linking opDNA supply with TriLink’s GMP mRNA manufacturing.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
